---
document_datetime: 2025-02-10 16:32:10
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/ituxredi-epar-all-authorised-presentations_en.pdf
document_name: ituxredi-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 1.0804145
conversion_datetime: 2025-12-23 21:11:14.877213
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Annex A

<div style=\"page-break-after: always\"></div>

| MA (EU) number   | (Invented) name   | Strength   | Pharmaceutical Form                   | Route of Administration   | Immediate Packaging   | Content (concentration)   | Pack size   |
|------------------|-------------------|------------|---------------------------------------|---------------------------|-----------------------|---------------------------|-------------|
| EU/1/24/1861/001 | Ituxredi          | 100 mg     | Concentrate for solution for infusion | Intravenous use           | vial (glass)          | 10 ml (10 mg/ml)          | 1 vial      |
| EU/1/24/1861/002 | Ituxredi          | 100 mg     | Concentrate for solution for infusion | Intravenous use           | vial (glass)          | 10 ml (10 mg/ml)          | 2 vials     |
| EU/1/24/1861/003 | Ituxredi          | 500 mg     | Concentrate for solution for infusion | Intravenous use           | vial (glass)          | 50 ml (10 mg/ml)          | 1 vial      |
| EU/1/24/1861/004 | Ituxredi          | 500 mg     | Concentrate for solution for infusion | Intravenous use           | vial (glass)          | 50 ml (10 mg/ml)          | 2 vials     |